Please login to the form below
Gleevec/Glivec
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Gleevec/Glivec was produced by Novartis.
WHO to test three more potential COVID-19 treatments
The drug will be administered intravenously for seven days. Hailed as a miracle anticancer drug when it was launched in 2008, Novartis’ Gleevec (imatinib), a small molecule tyrosine kinase inhibitor, may
FDA clears Blueprint’s $32k-per-month GI cancer drug
Chemotherapy and radiotherapy is notoriously ineffective in GIST. At the moment the standard approach to treating patients who aren’t eligible for surgery is older kinase inhibitor drugs like Novartis’ Glivec
Novartis aims for 10 blockbuster launches by 2020
On the downside, revenues from post-patent expiry cancer drug Glivec continued to decline (down 20% to $1.56bn).
Biopharma's Future: Made in China
Novartis’ leukaemia treatment Glivec.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- World Health Organization releases new road map for breast cancer
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Making new year resolutions that can also benefit others
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP
- Europe’s cancer community publishes new report on transforming patient care
- Assessing the value of interim analyses in clinical trials
- Piloting a route to the biosimilars opportunities in Europe
- Pre-launch planning and DSLs – the new ways to create launch excellence in pharma
PMHub
Evoke Kyne
Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
